close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hemab Therapeutics Holdings, Inc. - Common Stock (NQ:COAG)

35.82 -0.91 (-2.48%)
Streaming Delayed Price Updated: 10:01 AM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,206
Open 36.89
Bid (Size) 35.63 (100)
Ask (Size) 36.20 (100)
Prev. Close 36.73
Today's Range 35.75 - 37.64
52wk Range 23.00 - 55.42
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Hemab Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+5.4%
+5.4%
1 Month
-23.2%
-23.2%
3 Month
+24.6%
+24.6%
6 Month
+5.4%
+5.4%
1 Year
+5.4%
+5.4%

More News

Read More
News headline image
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans ↗
Via MarketBeat
News headline image
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Reports First Quarter 2026 Financial Results
From Hemab Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Hemab Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Hemab Therapeutics Holdings, Inc. - Common Stock publicly traded?
Yes, Hemab Therapeutics Holdings, Inc. - Common Stock is publicly traded.
What exchange does Hemab Therapeutics Holdings, Inc. - Common Stock trade on?
Hemab Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Hemab Therapeutics Holdings, Inc. - Common Stock?
The ticker symbol for Hemab Therapeutics Holdings, Inc. - Common Stock is COAG on the Nasdaq Stock Market
What is the current price of Hemab Therapeutics Holdings, Inc. - Common Stock?
The current price of Hemab Therapeutics Holdings, Inc. - Common Stock is 35.82
When was Hemab Therapeutics Holdings, Inc. - Common Stock last traded?
The last trade of Hemab Therapeutics Holdings, Inc. - Common Stock was at 09/24/26 10:01 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.